Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Hepatic Artery Catheter Clear all

Conditions: Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma
Interventions: Aldesleukin, Autologous CD8+ SLC45A2-specific T Lymphocytes, Cyclophosphamide, Ipilimumab; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Solid Tumor Cancer, Recurrent Head and Neck Cancer
Interventions: Ad-P53, Xeloda, Keytruda, Opdivo; Drug
Lead sponsor: MultiVir, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Colorectal Cancer Metastatic to Liver, Intrahepatic Cholangiocarcinoma
Interventions: Medtronic SynchroMed II programmable pump connected to an Intera tapered catheter (Combined Infusion System); Device
Lead sponsor: Ronald DeMatteo, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Liver Metastases, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions: irinotecan-eluting beads, hepatic artery embolization; Combination Product · Procedure
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pancreaticoduodenectomy, Hepatectomy
Interventions: Normovolemic Hemodilution (ANH), Standard of care; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Neuroendocrine Tumor
Interventions: 90Y-DOTA-TOC, 68Ga-DOTA-TOC; Drug
Lead sponsor: Thomas Hope; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Neuroendocrine Tumors, Gastrointestinal Neoplasms, Carcinoid Tumors
Interventions: Lanreotide, Y-90 microspheres; Drug · Device
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 3
States / cities: Denver, Colorado • Kansas City, Missouri • Nashville, Tennessee

Conditions: Ascites, Liver Cirrhosis, Hypertension, Portal
Interventions: Proximal Splenic Artery Embolization; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Neuroendocrine Tumors
Interventions: Pasireotide, Sir-sphere Radioembolization, Everolimus; Drug · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Liver Tumors, Hepatocellular Carcinoma, Hepatoma, Neoplasms
Interventions: TheraSphere®; Device
Lead sponsor: St. Joseph Hospital of Orange; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 1
States / cities: Orange, California

Conditions: Locally Advanced Unresectable Pancreatic Adenocarcinoma
Interventions: Padeliporfin Vascular Targeted Photodynamic (VTP) therapy; Combination Product
Lead sponsor: Impact Biotech Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Duarte, California • Irvine, California

Conditions: Liver Cancer, Liver Neoplasms, HepatoCellular Carcinoma
Interventions: TheraSphere Treatment; Device
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Unresectable Colorectal Liver Metastases
Interventions: Oxaliplatin; Drug
Lead sponsor: David Bartlett; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania

Conditions: Liver Cancer
Interventions: Perihepatic Phlebotomy; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Cancer, Metastatic Cancer
Interventions: dexamethasone, floxuridine, fluorouracil, leucovorin calcium, laparotomy, conventional surgery; Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2006
U.S. locations: 11
States / cities: Cedar Rapids, Iowa • Des Moines, Iowa • Papillion, Nebraska + 5 more

Conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
Interventions: thalidomide, doxorubicin hydrochloride, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Melanoma, Liver Metastasis
Interventions: Nab-Paclitaxel (Abraxane); Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Liver, Cancer of, Non-Resectable
Interventions: TheraSphere; Device
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Liver Cancer, Advanced Cancers, Solid Tumors
Interventions: HAI Abraxane, Hepatic Artery Catheter, IV Abraxane; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bile Duct Neoplasms, Colorectal Neoplasms
Interventions: Hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter., Hepatic artery infusion pump floxuridine and dexamethasone, Systemic chemotherapy for colorectal liver metastases, Systemic chemotherapy for intrahepatic cholangiocarcinoma; Device · Drug
Lead sponsor: Michael J Cavnar, MD; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Hepatocellular Carcinoma
Interventions: DEB-TACE; Procedure
Lead sponsor: Surefire Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 11
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 6 more

Conditions: Colorectal Neoplasms
Interventions: SIR-Spheres, Regorafenib; Device · Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: St. Petersburg, Florida • Kansas City, Missouri • Nashville, Tennessee

Conditions: Uveal Melanoma, Liver Metastases
Interventions: GM-CSF, Embolization; Drug · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Advanced Cancers
Interventions: Oxaliplatin, Capecitabine, Bevacizumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer

Infusion System for Hepatic Cancer

Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer

Acute Normovolemic Hemodilution Versus Standard Intraoperative Management in Patients Having Hepatic Resection and Pancreaticoduodenectomy

Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor

Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres

Proximal Splenic Artery Embolization (PSAE) for the Treatment of Refractory Ascites in Decompensated Cirrhosis

Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases

A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®

Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma

Therasphere for Unresectable Primary or Secondary Liver Neoplasia

Isolated Liver Perfusion With Oxaliplatin

A Pilot Study of Perihepatic Phlebotomy During Hepatic Resections

Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer

Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery

Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver

TheraSphere & Treatment of Unresectable Primary or Unresectable Secondary Liver Cancer

Hepatic Arterial Infusion (HAI) of Abraxane

Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma

DEB-TACE for Hepatocellular Carcinoma

Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases

Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF

Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab